The market has NASH fatigue, especially with early stage results. It showed with Arrowhead and Hepion last year after they announced preliminary results and more comprehensive releases of their data later didn't move the needle either.

Add that to the general market being down, small caps being out of favor lately and with possible Fife selling and you get what's happened today.